

Contents lists available at [ScienceDirect](http://www.elsevier.com/locate/redox)

## Redox Biology

journal homepage: [www.elsevier.com/locate/redox](http://www.elsevier.com/locate/redox)

## Research paper

## Direct spectrophotometric measurement of supra-physiological levels of ascorbate in plasma

Jordan R. Witmer, Bailey J. Wetherell, Brett A. Wagner, Juan Du, Joseph J. Cullen, Garry R. Buettner\*

Department of Radiation Oncology, Free Radical and Radiation Biology Program, B180 Medical Laboratories, The University of Iowa, Iowa City, IA 52242-1181, United States

## ARTICLE INFO

## Article history:

Received 9 December 2015

Received in revised form

11 February 2016

Accepted 12 February 2016

Available online 13 February 2016

## Keywords:

Ascorbate

Blood plasma

Spectrophotometric determination

## ABSTRACT

**Background:** Supra-physiological concentrations of ascorbate, vitamin C, in blood, greater than 1 mM, achieved through intravenous administration (IV), are being tested in clinical trials to treat human disease, e.g. cancer. These trials need information on the high levels of ascorbate achieved in blood upon IV administration of pharmacological ascorbate so appropriate clinical decisions can be made.

**Methods:** Here we demonstrate that in the complex matrix of human blood plasma supra-physiological levels of ascorbate can be quantified by direct UV spectroscopy with use of a microvolume UV-vis spectrophotometer.

**Results:** Direct quantitation of ascorbate in plasma in the range of 2.9 mM, lower limit of detection, up to at least 35 mM can be achieved without any sample processing, other than centrifugation.

**Conclusions:** This approach is rapid, economical, and can be used to quantify supraphysiological blood levels of ascorbate associated with the use of IV administration of pharmacological ascorbate to treat disease.

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

Since the discovery of vitamin C, ascorbic acid/ascorbate ( $\text{AsCH}_2/\text{AsCH}^-$ ) [1], many methods for its analysis in foods, biological fluids, and tissues have been developed. In human blood plasma concentrations of  $\text{AsCH}^-$  in the range of  $\approx 40\text{--}80\ \mu\text{M}$  are considered normal and healthy [2]. The highest concentration of  $\text{AsCH}^-$  that can be achieved in blood plasma via oral administration is on the order of  $200\ \mu\text{M}$  or so [3]. However, supra-physiological concentrations in blood,  $\approx 10,000$  to  $30,000\ \mu\text{M}$  or more, achieved through intravenous administration (IV), are being tested in clinical trials to treat human disease, e.g. cancer [4–9]. These types of trials need information on the high levels of  $\text{AsCH}^-$  achieved in blood upon IV administration of pharmacological  $\text{AsCH}^-$  so appropriate clinical decisions can be made. Thus, rapid and economical assays for these high levels of  $\text{AsCH}^-$  in blood plasma/serum are needed.

\* Correspondence to: Free Radical and Radiation Biology Radiation, Oncology and ESR Facility, Med Labs B180, The University of Iowa, Iowa City, IA 52242-1181, United States.

E-mail addresses: [jordan.witmer@gmail.com](mailto:jordan.witmer@gmail.com) (J.R. Witmer), [wetherb@uiowa.edu](mailto:wetherb@uiowa.edu) (B.J. Wetherell), [brett-wagner@uiowa.edu](mailto:brett-wagner@uiowa.edu) (B.A. Wagner), [juan-du@uiowa.edu](mailto:juan-du@uiowa.edu) (J. Du), [joseph-cullen@uiowa.edu](mailto:joseph-cullen@uiowa.edu) (J.J. Cullen), [garry-buettner@uiowa.edu](mailto:garry-buettner@uiowa.edu) (G.R. Buettner).

<http://dx.doi.org/10.1016/j.redox.2016.02.004>

2213-2317/© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

A wide variety of assays for the levels of  $\text{AsCH}^-$  in cultured cells, biological fluids, and tissues have been developed: direct measurement via HPLC [10–12], colorimetric methods [13], fluorescence of products formed upon reaction with dehydroascorbic acid [14,15], use of the chemistry in a fingerstick blood glucose monitor [16], and by electron paramagnetic spectroscopy [17].

Ascorbic acid is a diprotic acid with  $\text{pK}_{a1}=4.0$  at an ionic strength of 150 mM and  $\text{pK}_{a2}=11.5$  [18–20]. Thus, at near-neutral pH, the dominant form will be the  $\text{AsCH}^-$  monoanion. Ascorbic acid and the  $\text{AsCH}^-$  monoanion have distinctly different ultraviolet (UV) spectra. The diprotic acid,  $\text{AsCH}_2$ , has a maximum molar absorptivity at 243 nm,  $\epsilon_{243}=9650\ \text{M}^{-1}\text{cm}^{-1}$  [21]. The  $\text{AsCH}^-$  monoanion has an absorption maximum at 265 nm. Many values for its molar absorptivity have been reported, with  $\epsilon_{265}$  ranging from  $7500$  to  $20,400\ \text{M}^{-1}\text{cm}^{-1}$  [20,21]. A careful study found  $\epsilon_{265}=14,560 \pm 450\ \text{M}^{-1}\text{cm}^{-1}$  and  $\epsilon_{251}=8250 \pm 150\ \text{M}^{-1}\text{cm}^{-1}$  at the isobestic point (250.7 nm) for the diacid and the monoanion [21]. When unwanted oxidation is avoided,  $\epsilon_{265}=14,500\ \text{M}^{-1}\text{cm}^{-1}$  is the maximum UV absorbance of  $\text{AsCH}^-$  [22]. These values for the molar absorptivity allow quantification of  $\text{AsCH}^-$  in aqueous buffers when  $[\text{AsCH}^-]$  is greater than about  $5\ \mu\text{M}$  using a typical UV spectrophotometer (1.00 cm cuvette).

Here we propose that in the complex matrix of human blood plasma supra-physiological  $[\text{AsCH}^-]$  of 3–30 mM, achieved by IV administration [4], can be quantified by direct UV spectroscopy.

Use of a microvolume UV–vis spectrophotometer will allow quantitation in plasma without any sample processing (*i.e.* no chemistries and no dilutions), other than centrifugation of the whole blood to deplete platelets and remove red blood cells.

## 2. Materials and methods

### 2.1. Plasma samples

Blood plasma samples were from subjects of clinical trials being conducted at The University of Iowa that are investigating the use of pharmacological AsC<sup>H</sup><sup>−</sup> as an adjuvant in the treatment of cancer. These trials were approved by The University of Iowa IRB and are listed on <https://clinicaltrials.gov> [4–6]. Whole blood was collected using BD Vacutainer<sup>®</sup> green top blood collection tube, 4 mL, NaHeparin 75 USP units. Samples were centrifuged at 2000g for 15 min; RBC-free, platelet-depleted plasma was collected for analysis. The plasma was divided into aliquots (650  $\mu$ L) and analyzed for AsC<sup>H</sup><sup>−</sup> immediately or stored at  $-80^{\circ}\text{C}$  for later analysis. We found that AsC<sup>H</sup><sup>−</sup> in plasma was quite stable for long periods of time at  $-80^{\circ}\text{C}$ , consistent with detailed studies on the stability of AsC<sup>H</sup><sup>−</sup> in plasma [23–25].

### 2.2. UV/Vis spectroscopy

#### 2.2.1. Standard curve

A 0.100 M [AsC<sup>H</sup><sup>−</sup>] standard solution (10.0 mL) was prepared in a phosphate buffer, PBS pH=7.0 with [phosphate]=100 mM; all buffers were treated with chelating resin to remove adventitious catalytic metals [22]. The exact concentration of the stock solution was verified by absorbance at 265 nm,  $\epsilon_{265}=14,500\text{ M}^{-1}\text{ cm}^{-1}$  [22]. Absorbance measurements were accomplished using an Implen Nanophotometer P-330 with a 250 $\times$  dilution lid, path length= $4.00\times 10^{-3}\text{ cm}$ , *i.e.* 40  $\mu$ m. Nine separate dilutions using the 0.100 M [AsC<sup>H</sup><sup>−</sup>] stock solution and PBS pH=7.0 buffer were made. The concentrations of these standard solutions (250  $\mu$ L total volume each) were: 35.0, 30.0, 25.0, 20.0, 15.0, 10.0, 5.0, 2.5, 1.3, and 0.0 mM.

All standard curve samples were examined in triplicate. The standard curve was prepared using the median obtained for each standard [26].

#### 2.2.2. Standard addition

Using standard solutions of AsC<sup>H</sup><sup>−</sup>, a standard addition was made to plasma samples obtained from four different subjects. Absorbance measurements at 265 nm were accomplished using an Implen Nanophotometer P-330 with a 250 $\times$  dilution lid (path length= $4.00\times 10^{-3}\text{ cm}$ =40  $\mu$ m). Nine separate standard additions using the 0.100 M [AsC<sup>H</sup><sup>−</sup>] stock solution in plasma samples were made. The concentrations of these standard additions (250  $\mu$ L total volume each) were: 35.0, 30.0, 25.0, 20.0, 15.0, 10.0, 5.0, 2.5, 1.3, and 0.0 mM. Care must be taken to thoroughly clean the lid and cuvette surfaces as AsC<sup>H</sup><sup>−</sup> quickly crystallizes out of solution leading to incorrect readings of absorbance.

All experimental samples were examined in triplicate. To determine the absorbance due to AsC<sup>H</sup><sup>−</sup> at 265 nm any absorbance from the 0.0 mM sample was subtracted out. The standard addition curve was prepared using the median obtained for each standard [26].

#### 2.2.3. Reduction of dehydroascorbic acid to ascorbate

We confirmed that plasma samples had undetectable amounts of dehydroascorbic acid (DHA), the two-electron oxidation product of AsC<sup>H</sup><sup>−</sup>, by addition of dithiothreitol (DTT). A stock solution of DHA was made in 10  $\mu$ M phosphate buffer, pH 6.5, by adding

10 mg of DHA to 1.00 mL buffer; a working solution was made by diluting 1.5  $\mu$ L of stock solution into 1.00 mL of buffer yielding 86  $\mu$ M DHA. A stock DTT solution was prepared with 50 mg of DTT solubilized into 1.00 mL of 10  $\mu$ M phosphate buffer, pH 6.5. A blank with deionized water was collected using a 1.00 cm path length cuvette in an Implen Nanophotometer. The working solution of DHA was added and a baseline spectrum, 250–900 nm, was obtained. As soon as possible after adding and mixing 4  $\mu$ L of DTT stock another spectrum was obtained. Then additional spectra were captured at 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240, and 300 s after mixing with DTT.

#### 2.2.4. Statistical approaches

All margins of error displayed in graphs and provided in the text were determined using Igor 5.03 software (WaveMetrics, Inc., Lake Oswego, OR) and represent one standard deviation. The lower limit of detection for [AsC<sup>H</sup><sup>−</sup>] in neutral buffer was found to be 2.9 mM as determined using the calibration plot method [27]. All uncertainties presented are standard deviations unless noted otherwise. Precision was addressed by repeated measurements of absorbance of the plasma at 265 nm from a single subject using an Implen Nanophotometer P-330 with a 250 $\times$  dilution lid. Absorbance of both the pre-infusion and post-infusion plasma was determined ten or more times on 5 different days.


## 3. Results and discussion

### 3.1. UV/Vis spectra of known concentrations of ascorbate in pH neutral buffer

To determine the response of the microvolume UV/Vis spectrometer to AsC<sup>H</sup><sup>−</sup> in typical near-neutral buffer, aliquots of an AsC<sup>H</sup><sup>−</sup> standard solution, prepared gravimetrically, were added to Chelex<sup>®</sup>-treated phosphate buffer (100 mM, pH 7.0) to achieve a series of known concentrations, 0–35 mM. Using a microvolume UV/Vis spectrometer in conjunction with a 250 $\times$  dilution lid (path length= $4.00\times 10^{-3}\text{ cm}$ =40  $\mu$ m), spectra were captured for the various [AsC<sup>H</sup><sup>−</sup>], Fig. 1. Using  $\epsilon_{265}=14,500\text{ M}^{-1}\text{ cm}^{-1}$  [22], a plot of the measured concentrations of AsC<sup>H</sup><sup>−</sup> (ordinate) vs. the concentration of the gravimetrically prepared standard (abscissa) showed the expected linear response, slope=0.91,  $R^2=0.998$ . Concentrations from 2.9 mM, lower limit of detection, up to at least 35 mM can be determined directly with no dilution [27]. A 35 mM solution of AsC<sup>H</sup><sup>−</sup> in a 1.00 cm cuvette would have a theoretical absorbance of 508 at 265 nm. These results indicate that use of a microvolume UV/Vis spectrometer has the potential for use to assess quickly pharmacological [AsC<sup>H</sup><sup>−</sup>] in plasma.

### 3.2. Ascorbate concentrations in blood plasma after standard additions of ascorbate

In order to examine the potential for the direct detection of AsC<sup>H</sup><sup>−</sup> in plasma using a microvolume UV/Vis spectrometer, standard additions of AsC<sup>H</sup><sup>−</sup> were made to blood plasma samples from four different subjects to achieve known concentrations ranging from 0.0 to 35.0 mM. As expected, with no addition of AsC<sup>H</sup><sup>−</sup>, there is an absorbance in the same region as the AsC<sup>H</sup><sup>−</sup> absorption due to the protein in the plasma. Addition of known amounts of AsC<sup>H</sup><sup>−</sup> to the samples of plasma resulted in increasing absorbance at 265 nm, Fig. 2. The concentration of AsC<sup>H</sup><sup>−</sup> from the absorbance measurement of the microvolume UV/Vis spectrometer (ordinate) was calculated by subtracting the absorbance of the baseline from each standard addition of AsC<sup>H</sup><sup>−</sup> and applying the path length,  $4.00\times 10^{-3}\text{ cm}$ , and molar extinction coefficient  $\epsilon_{265}=14,500\text{ M}^{-1}\text{ cm}^{-1}$  [22]. An excellent linear correlation was



**Fig. 1.** UV/Vis spectra of known concentrations of ascorbate in pH neutral buffer. Aliquots of an  $\text{AscH}^-$  standard solution, prepared gravimetrically, were added to Chelexed phosphate buffer (100 mM, pH 7.0) to achieve a series of known concentrations. An Implen Nanophotometer P-330 with  $250\times$  dilution lid (path length =  $4.00 \times 10^{-3}$  cm) was used to gather spectra. (A) A plot of one set of spectra of various  $[\text{AscH}^-]$  (0.0, 1.3, 2.5, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, and 35.0 mM). (B) The measured  $[\text{AscH}^-]$  (ordinate) were determined using  $\epsilon_{265} = 14,500 \text{ M}^{-1} \text{ cm}^{-1}$  [21,22] are plotted against the concentration of the gravimetrically prepared standard (abscissa); slope =  $0.91 \pm 0.02$ ,  $R^2 = 0.998$ . The blank was buffer only.

found, Fig. 2B. Thus, using a microvolume UV/Vis spectrometer, the levels of  $\text{AscH}^-$  in plasma, 2.9 mM lower limit of detection, up to at least 35 mM can be determined directly with no sample processing.

To estimate the effective molar extinction coefficient for  $\text{AscH}^-$  in plasma at 265 nm a plot of the absorbance obtained directly from the Implen Nanophotometer P-330 with a  $250\times$  dilution lid vs. the known standard was made, Fig. 2C. The slope of this line will yield the apparent molar extinction coefficient in the matrix of plasma. This line has a slope =  $0.053 \pm 0.002 \text{ mM}^{-1}$ ; in standard units for molar extinction coefficients, this slope yields  $\epsilon_{265} = 13,000 \pm 500 \text{ M}^{-1} \text{ cm}^{-1}$ .

### 3.3. The direct assay agrees well with results from a fluorescence plate reader assay

In order to determine how the results of the direct assay for  $\text{AscH}^-$  in plasma using a microvolume UV-vis spectrophotometer agree with another assay, we analyzed a large set of plasma samples ( $n=179$ ) from subjects that were participating in clinical trials of pharmacological  $\text{AscH}^-$  as an adjuvant in cancer treatment [4–6]. The plasma samples from the trials were analyzed using a kinetic-based assay [4,15]. We found remarkable agreement between the plasma concentrations determined for  $\text{AscH}^-$  by these two very different assays, as manifest in the slope of 1.00 when plotting the  $[\text{AscH}^-]$  for each assay, Fig. 3.


Many assays for  $[\text{AscH}^-]$  in plasma precipitate the protein [12,15]. This results in a decrease in the effective volume of the plasma sample; as a result the  $[\text{AscH}^-]$  in the plasma will be overestimated. The partial specific volume of protein is approximately  $0.73 \text{ cm}^3 \text{ g}^{-1}$  [28]. Plasma is 7.5% protein, or  $75 \text{ g L}^{-1}$ ; thus,  $(75 \text{ g}/1000 \text{ mL}) \times (0.73 \text{ cm}^3/\text{g}) \times 100\% = 5.5\%$  of the volume of plasma is protein. If this protein is removed, then the  $[\text{AscH}^-]$  will be concentrated by  $\approx 5.8\%$  ( $100/94.5$ ). In the direct assay using a microvolume UV/Vis spectrometer the protein is not removed while in the kinetic fluorescence assay it is removed. If the correction for protein volume is not made, then the slope through the origin in Fig. 3 is 0.95, exactly as predicted. This demonstrates the importance of considering the volume of protein, if removed in any type of quantitative assay.

### 3.4. Ascorbate concentrations determined in plasma using an average blank

In Fig. 3 the blank for each sample was the plasma from a blood sample drawn just before infusion of pharmacological  $\text{AscH}^-$ . However, such a sample may not always be available nor needed to minimize discomfort and risk. To determine if an average blank for the absorbance at 265 nm can be used, 170 samples were analyzed for the concentration of  $\text{AscH}^-$ . A comparison was made between the results using the average absorbance at 265 nm of all 170 samples as a blank compared to using the pre-infusion blood sample as a blank for each subject, Fig. 4. For the values of the abscissa the blank was the corresponding plasma of each subject taken prior to infusion of pharmacological  $\text{AscH}^-$ . For the ordinate the blank was the average of the absorbance at 265 nm ( $0.23 \pm 0.04$ , path length =  $4.00 \times 10^{-3}$  cm) of the pre-infusion samples for all 170 subjects. A slope of 0.98 demonstrates that an average blank can be used to estimate the supra-physiological  $[\text{AscH}^-]$ . Thus, a pre-infusion sample of plasma is not necessary.

To estimate the precision of the assay, the absorbance at 265 nm from a single sample of plasma was determined multiple times ( $n \geq 10$ ) on five different days. The absorbance values at 265 nm for the pre-infusion samples were, in order of day 1-day 5, mean, medium, (standard deviation): 0.16, 0.15, (0.01); 0.21, 0.20, (0.03); 0.22, 0.22, (0.02); 0.23, 0.23, (0.02); and 0.19, 0.19, (0.01); respectfully. The absorbance at 265 nm for the post-infusion samples were, in order of day 1 to day 5, mean, medium, (standard deviation): 1.01, 0.98, (0.08); 1.11, 1.07, (0.12); 1.03, 1.02, (0.05); 1.06, 1.03, (0.11); and 1.00, 0.99, (0.04); respectfully. The coefficient of variation for each day was determined and the average for the pre-infusion was found to be 9.4% and for the post-infusion, 7.8%.

Using these absorbance data, path length =  $4.00 \times 10^{-3}$  cm, and  $\epsilon_{265} = 13,000 \text{ M}^{-1} \text{ cm}^{-1}$ , the estimated concentration of  $\text{AscH}^-$  from each the five days would be: 16.0, 16.7, 15.4, 15.4, 15.4 mM; median = 15.4 mM. If one uses the average absorbance of  $0.23 \pm 0.04$  for the blank, the estimated concentration of  $\text{AscH}^-$  from each the five days would be: 14.4, 16.2, 15.2, 15.4, 14.6; median = 15.2 mM, excellent agreement between the two approaches.




**Fig. 2.** Spectrophotometric determination of ascorbate concentrations in blood plasma after standard additions of ascorbate. Standard additions of AscH<sup>-</sup> were made to blood plasma samples from four different subjects to achieve known concentrations of 0.0, 1.3, 2.5, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, and 35.0 mM. Absorbance was determined using an Implen Nanophotometer P-330 with 250 $\times$  dilution lid, i.e. path length =  $4.00 \times 10^{-3}$  cm. (A) One set of example spectra obtained after the standard additions to the plasma of one subject. (B) The measured AscH<sup>-</sup> concentration (ordinate) was calculated by taking the difference between absorbance of the baseline, 0.0 mM AscH<sup>-</sup>, from each standard addition of AscH<sup>-</sup>. The difference was then used to determine the measured [AscH<sup>-</sup>] using  $\epsilon_{265} = 14,500$  M<sup>-1</sup> cm<sup>-1</sup> [21]. From these data a plot was generated using the median values obtained from the measured [AscH<sup>-</sup>] and plotted against the known gravimetric standard; slope =  $0.98 \pm 0.02$ ,  $R^2 = 0.996$ . (C) A plot of the absorbance obtained directly from the Implen Nanophotometer P-330 with a 250 $\times$  dilution lid is plotted against the known gravimetric standard; slope =  $0.053 \pm 0.002$  mM<sup>-1</sup> 250<sup>-1</sup> cm<sup>-1</sup>. Converting this to standard units for the molar extinction coefficient and accounting for the dilution,  $\epsilon_{265 \text{ nm}} = 13,000 \pm 500$  M<sup>-1</sup> cm<sup>-1</sup>. This is the apparent molar extinction coefficient for AscH<sup>-</sup> in plasma. All measurements were done in triplicate.

Uncertainties will add in quadrature (square root of the sum of the squares of the coefficients of variation) yielding a coefficient of variation of about 13%, if a pre-infusion sample is available as a blank. If the average blank is used, then the estimated coefficient of variation would be about 20%, the largest contribution coming from the biological variation in the absorbance of the plasma at 265 nm. Normal levels of AscH<sup>-</sup> in plasma range from  $\approx 40$ – $80$   $\mu$ M; these levels of AscH<sup>-</sup> in plasma would contribute 0.002–0.004 absorbance units to the blank ( $4.00 \times 10^{-3}$  cm path length), i.e. at the noise level. Thus, if an average blank is used, the variation observed is, as expected, from the biological variation in the protein content of plasma [29].

### 3.5. The reduction of dehydroascorbic acid to ascorbate by dithiothreitol is rapid

Ascorbate can readily undergo oxidation, resulting in formation of DHA. It has long been known that thiols such as glutathione will reduce DHA back to AscH<sup>-</sup> [30]. To determine if a significant amount of the AscH<sup>-</sup> had oxidized to DHA we used dithiothreitol (DTT) as a reducing agent [31]. When an excess of DTT was added to DHA in near-neutral buffer, the reduction to AscH<sup>-</sup> was rapid, within 3 min, Fig. 5. Analysis of the plot of absorbance at 265 nm vs. time, assuming a pseudo first-order reaction (in DTT) and fitting to a single exponential, yields a pseudo first-order rate





**Fig. 3.** The direct assay using an Implen Nanophotometer agrees well with results from the fluorescence plate reader assay. Using the  $[\text{AsCH}^-]$  from the fluorescence plate reader assay [15] adjusted for protein precipitation [28] and the  $[\text{AsCH}^-]$  from the direct UV/Vis Implen Nanophotometer assay, 179 different samples from subjects were analyzed for  $\text{AsCH}^-$ . For each sample, the blank used was the plasma from a blood sample drawn just before infusion of pharmacological  $\text{AsCH}^-$  in a treatment session [4–6]. The linear regression that is set to go through the origin yields a slope of  $1.00 \pm 0.01$  and  $R^2 = 0.78$ .

constant of  $k' = 3.0 \times 10^{-2} \text{ s}^{-1}$ , and  $k = 9.4 \text{ M}^{-1} \text{ s}^{-1}$  as a second-order rate constant for the reaction  $\text{DHA} + \text{DTT} \rightarrow \text{AsCH}^- + \text{DTT}_{\text{oxidized}}$  under these experimental conditions. This is consistent with the observed rate constant  $k_{\text{obs}} = 0.3 \text{ M}^{-1} \text{ s}^{-1}$  at pH 7.4 for the reaction of glutathione with DHA, as determined from the data presented in [32].


When we added DTT to plasma samples, such as those of Fig. 5, and took an absorbance reading 10 min later, no changes in absorbances were observed, other than dilution, indicating our sample handling protocols resulted in no significant oxidation of  $\text{AsCH}^-$ .

### 3.6. Ascorbate specificity


As many biological compounds absorb light in the UV, a simple approach to confirm that  $\text{AsCH}^-$  is the analyte being detected at 265 nm is to collect the spectrum ranging from around 200 nm to at least 350 nm. The peak absorbance of  $\text{AsCH}^-$  at 265 nm will be the peak of the spectrum; it should not be on the shoulder of the absorption spectrum; the absorbance should begin around 230 nm and end around 300 nm, Fig. 2A. Because the concentration of  $\text{AsCH}^-$  can be on the order of 20 mM, the only interference expected would be from a xenobiotic, not from endogenous proteins or other natural components of plasma.

### 3.7. Easy clinical implementation

This technique can be easily implemented in a clinical setting. The spectrophotometer used here has a small footprint,  $\approx 25 \text{ cm} \times \approx 50 \text{ cm}$ , does not require an external computer, and can independently print data as a record. The protocol is



**Fig. 4.** Ascorbate concentrations determined with “post-infusion – average blank” vs. “post-infusion – pre-infusion” with differences plotted as residual. Using the absorbance at 265 nm, 169 samples were analyzed for the concentration of  $\text{AsCH}^-$ . For the values of the abscissa the blank was the corresponding plasma of each subject taken prior to infusion, i.e. pre-infusion, of pharmacological  $\text{AsCH}^-$ . For the ordinate the blank was the average of the absorbance at 265 nm ( $0.23 \pm 0.04$ ), path length  $= 4.00 \times 10^{-3} \text{ cm}$ , of the pre-infusion samples for all 169 subjects. The upper plot shows the residuals (ordinate value – abscissa value) between the two measurements. The slope of  $0.96 \pm 0.01$  demonstrates the ability to estimate supra-physiological  $\text{AsCH}^-$  concentrations even if a pre-infusion plasma sample is not available.



**Fig. 5.** The reduction of dehydroascorbate to ascorbate by dithiothreitol is rapid. Dehydroascorbic acid (DHA;  $86 \mu\text{M}$ ) in Chelex<sup>®</sup>-treated phosphate buffer ( $10 \mu\text{M}$ , pH 6.5) was dispensed into a 1.00 cm path length cuvette and the UV-vis absorbance was monitored using an Implen Nanophotometer P-330. The Nanophotometer was blanked with a  $10 \mu\text{M}$  phosphate buffer, pH 6.5. The solid line with an absorbance near 0.0 AU at 265 nm is the spectrum for  $86 \mu\text{M}$  DHA. Upon addition of  $3200 \mu\text{M}$  dithiothreitol (DTT) the spectra show the time-dependent increase in the concentration of  $\text{AsCH}^-$  due to the reduction of DHA by DTT to  $\text{AsCH}^-$ . (Inset) The plot shows the change in the absorbance at 265 nm vs. time. Assuming a pseudo first-order reaction (in DTT) and fitting to a single exponential a pseudo first-order rate constant yields  $k' = (3.0 \pm 0.01) \times 10^{-2} \text{ s}^{-1}$ , and  $k = 9.4 \text{ M}^{-1} \text{ s}^{-1}$  as a second-order rate constant for the reaction  $\text{DHA} + \text{DTT} \rightarrow \text{AsCH}^- + \text{DTT}_{\text{oxidized}}$  under these experimental conditions ( $n = 3$ ).

straightforward and requires only to blank the instrument with water as preparation when subtracting with the average plasma background, Fig. 4. The absorbance of the plasma can be read directly with minimal training; no dilutions, and no buffers make it possible to obtain data within a minute and immediately determine  $[\text{AsCH}^-]$  to make rapid clinical decisions.

#### 4. Conclusions

Here we demonstrate:

1. A microvolume UV/Vis spectrometer can be used to determine supra-physiological levels of  $\text{AsCH}^-$  in blood plasma directly (2.9 mM, lower limit of detection, to at least 35 mM), i.e. without the need for any sample processing;
2. With appropriate sample handling, oxidation of  $\text{AsCH}^-$  to DHA in the plasma is not a concern;
3. The effective molar extinction coefficient for the  $\text{AsCH}^-$  mono-anion in the matrix of blood plasma appears to be  $\epsilon_{265} = 13,000 \text{ M}^{-1} \text{ cm}^{-1}$ .
4. An average blank absorbance of 0.23 ( $4.00 \times 10^{-3} \text{ cm}$  path length) at 265 nm can be used to determine the  $[\text{AsCH}^-]$  in plasma using a microvolume UV/Vis spectrometer;
5. For an optical path length of  $4.00 \times 10^{-3} \text{ cm}$  (250  $\times$  dilution lid of an Implen Nanophotometer P-330) the concentration of  $\text{AsCH}^-$  in plasma (no dilution or processing) can be found using Eq. (1) when no pre-infusion sample is available, or using Eq. (2) when a pre-infusion sample is available:

$$[\text{AsCH}^-] = (\text{Absorbance}_{265} - 0.23) / (13,000 \text{ M}^{-1} \text{ cm}^{-1} \times 4.00 \times 10^{-3} \text{ cm}) \quad (1)$$

$$[\text{AsCH}^-] = (\text{Absorbance}_{265} - \text{Pre-infusion Absorbance}_{265}) / (13,000 \text{ M}^{-1} \text{ cm}^{-1} \times 4.00 \times 10^{-3} \text{ cm}) \quad (2)$$

These equations can be adjusted for other path lengths; the blank of Eq. (1) will need to be scaled appropriately. Here the goal was to assay for  $\text{AsCH}^-$  in plasma without employing any chemistries or dilutions. This basic assay can be employed upon dilution of the plasma sample to accommodate a standard 1.00 cm path length cuvette; attention must then be given to all aspects of the determination and the analysis.

6. Although the determination of the absorbance of a plasma sample at 265 nm has good precision, the resulting uncertainties in the concentration of  $\text{AsCH}^-$  in plasma have a coefficient of variation  $\approx 13\%$  if a pre-infusion sample is available to be used for the blank. If an average blank is used, then the coefficient of variation is  $\approx 20\%$ , because of the biological variation in the absorbance of plasma.

#### Acknowledgments

The authors declare that there are no competing interests. This publication was supported by the National Institutes of Health (NIH), Grants R01CA169046, R01GM073929, NIH 5 T32 CA078586, HL046925, R01 CA184051 and the Gateway for Cancer Research. The ESR Facility at the University of Iowa provided invaluable support. Core facilities were supported in part by the Holden Comprehensive Cancer Center, P30CA086862. The content is solely the responsibility of the authors and does not represent views of the National Institutes of Health.

#### References

- [1] A. Szent-Györgyi, Observations on the function of peroxidase systems and the chemistry of the adrenal cortex: description of a new carbohydrate derivative, *Biochem. J.* 22 (1928) 1387–1409, PMID: 16744155.
- [2] Institute of Medicine (US) Panel on Dietary Antioxidants and Related Compounds, Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids, National Academies Press (US), Washington (DC), 2000, PMID: 25077263; (<http://www.ncbi.nlm.nih.gov/books/NBK225483/>).
- [3] S.J. Padayatty, H. Sun, Y. Wang, H.D. Riordan, S.M. Hewitt, A. Katz, R.A. Wesley, M. Levine, Vitamin C pharmacokinetics: implications for oral and intravenous use, *Ann. Intern. Med.* 140 (7) (2004) 533–537, PMID: 15068981.
- [4] J.L. Welsh, B.A. Wagner, T.J. van't Erve, P.S. Zehr, D.J. Berg, T.R. Halfdanarson, N. S. Yee, K.L. Bodeker, J. Du, L.J. Roberts 2nd, M. Levine, G.R. Buettner, J.J. Cullen, Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial, *Cancer Chemother. Pharmacol.* 71 (3) (2013) 765–775, <http://dx.doi.org/10.1007/s00280-013-2070-8>, PMID: PMC3587047.
- [5] J.M. Buatti (PI), B. Allen, C. Anderson, D. Berg, S. Bhatia, K. Bodeker, G. Beuttner, W. Rockey, M. Smith, W. Sun, B. Wagner, (Start date 04/2013; Active and Recruiting), A phase 1 trial of high dose ascorbate in glioblastoma multiforme at The University of Iowa, (NCT01752491), (<http://clinicaltrials.gov/ct2/show/NCT01752491>).
- [6] J.J. Cullen (PI), D. Berg, J.M. Buatti, G.R. Buettner, M.C. Smith, C.M. Anderson, W. Sun, B.A. Allen, W. Rockey, D. Spitz, B. Wagner, S. Schroeder, R. Hohl, (Start date 01/2014; active and recruiting), Gemcitabine, Ascorbate, and Radiation Therapy for Pancreatic Cancer, Phase 1, at The University of Iowa, (NCT01852890), (<http://clinicaltrials.gov/ct2/show/NCT01852890>).
- [7] Y. Ma, J. Chapman, M. Levine, K. Polireddy, J. Drisko, Q. Chen, High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy, *Sci. Transl. Med.* 6 (222) (2014) 222ra18, <http://dx.doi.org/10.1126/scitranslmed.3007154>, PMID: 24500406.
- [8] L.J. Hoffer, M. Levine, S. Assouline, D. Melnychuk, S.J. Padayatty, K. Rosadiuk, C. Rousseau, L. Robitaille, W.H. Miller Jr, Phase I clinical trial of i.v. ascorbic acid in advanced malignancy, *Ann. Oncol.* 19 (2008) 1969–1974, <http://dx.doi.org/10.1093/annonc/mdn377> (<http://www.ncbi.nlm.nih.gov/pubmed/18544557>).
- [9] D.A. Monti, E. Mitchell, A.J. Bazzan, S. Littman, G. Zabrecky, C.J. Yeo, M.V. Pillai, A.B. Newberg, S. Deshmukh, M. Levine, Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer, *PLoS One* 7 (1) (2012) e29794, <http://dx.doi.org/10.1371/journal.pone.0029794>, PMID: 22272248.
- [10] P.W. Washko, W.O. Hartzell, M. Levine, Ascorbic acid analysis using high-performance liquid chromatography with coulometric electrochemical detection, *Anal. Biochem.* 181 (2) (1989) 276–282, PMID: 2817392.
- [11] J. Lykkesfeldt, S. Loft, H.E. Poulsen, Determination of ascorbic acid and dehydroascorbic acid in plasma by high-performance liquid chromatography with coulometric detection—are they reliable biomarkers of oxidative stress? *Anal. Biochem.* 229 (2) (1995), PMID: 7485991.
- [12] H. Li, H. Tu, Y. Wang, M. Levine, Vitamin C in mouse and human red blood cells: an HPLC assay, *Anal. Biochem.* 426 (2) (2012) 109–117, <http://dx.doi.org/10.1016/j.ab.2012.04.014>, PMID: 22522059.
- [13] T.Z. Liu, N. Chin, M.D. Kiser, W.N. Bigler, Specific spectrophotometry of ascorbic acid in serum or plasma by use of ascorbate oxidase, *Clin. Chem.* 28 (11) (1982) 2225–2228, PMID: 7127767.
- [14] G. Brubacher, J.P. Vuilleumier, Vitamin C, in: H.C. Curtius, M. Roth (Eds.), *Clinical Biochem, Principles and Methods*, Vol 2, de Gruyter, Berlin, 1974, pp. 989–997.
- [15] J.M. Vislisisel, F.Q. Schafer, G.R. Buettner, A simple and sensitive assay for ascorbate using a plate reader, *Anal. Biochem.* 365 (2007) 31–39, <http://dx.doi.org/10.1016/j.ab.2007.03.002>, PMID: PMC2129083.
- [16] Y. Ma, G. Sullivan, E. Schrick, I.Y. Choi, Z. He, J. Lierman, P. Lee, J.A. Drisko, Q. Chen, A convenient method for measuring blood ascorbate concentrations in patients receiving high-dose intravenous ascorbate, *J. Am. Coll. Nutr.* 32 (3) (2013), <http://dx.doi.org/10.1080/07315724.2013.791167>, PMID: 23885992.
- [17] R. Sasaki, T. Kurokawa, S. Tero-Kubota, Nature of serum ascorbate radical and its quantitative estimation, *Tohoku J. Exp. Med.* 136 (2) (1982) 113–119, PMID: 6280338.
- [18] E.G. Ball, Studies on oxidation-reduction: XXIII. Ascorbic acid, *J. Biol. Chem.* 118 (1937) 219–239.
- [19] M.M.T. Khan, A.E. Martel, Metal ion and metal chelate catalyzed oxidation of ascorbic acid by molecular oxygen. I. Cupric and ferric ion catalyzed oxidation, *J. Am. Chem. Soc.* 89 (16) (1967) 4176–4185.
- [20] S. Lewin, Vitamin C, Its Molecular Biology and Medical Potential, Academic Press, London, 1976.
- [21] M.I. Karayannis, D.N. Samios, C.P. Gousetis, A study of the molar absorptivity of ascorbic acid at different wavelengths and pH values, *Anal. Chim. Acta* 93 (1) (1977) 275–279, PMID: 20819.
- [22] G.R. Buettner, In the absence of catalytic metals, ascorbate does not autoxidize at pH 7: ascorbate as a test for catalytic metals, *J. Biochem. Biophys. Methods* 16 (1988) 27–40, [http://dx.doi.org/10.1016/0165-022X\(88\)90100-5](http://dx.doi.org/10.1016/0165-022X(88)90100-5).
- [23] D.W. Bradley, G. Emery, J.E. Maynard, Vitamin C in plasma: a comparative study of the vitamin stabilized with trichloroacetic acid or metaphosphoric acid and the effects of storage at  $-70$  degrees,  $-20$  degrees,  $4$  degrees, and  $25$  degrees on the stabilized vitamin, *Clin. Chim. Acta* 44 (1) (1973) 47–52, PMID: 4707637.

- [24] W. Lee, K.A. Davis, R.L. Rettmer, R.F. Labbe, Ascorbic acid status: biochemical and clinical considerations, *Am. J. Clin. Nutr.* 48 (2) (1988) 286–290, PMID: 3136641.
- [25] A. Karlsen, R. Blomhoff, T.E. Gundersen, Stability of whole blood and plasma ascorbic acid, *Eur. J. Clin. Nutr.* 61 (10) (2007) 1233–1236, <http://dx.doi.org/10.1038/sj.ejcn.1602655>, PMID: 17299479.
- [26] R.B. Dean, W.J. Dixon, Simplified statistics for small numbers of observations, *Anal. Chem.* 23 (4) (1951) 636–638, <http://dx.doi.org/10.1021/ac60052a025>.
- [27] D.J. Anderson, Determination of the lower limit of detection, *Clin. Chem.* 35 (10) (1989) 2152–2153, PMID: 2619804.
- [28] M. Häckel, H.J. Hinz, G.R. Hedwig, Partial molar volumes of proteins: amino acid side-chain contributions derived from the partial molar volumes of some tripeptides over the temperature range 10–90 degrees C, *Biophys. Chem.* 82 (1) (1999) 35–50, [http://dx.doi.org/10.1016/S0301-4622\(99\)00104-0](http://dx.doi.org/10.1016/S0301-4622(99)00104-0), PMID: 17030339.
- [29] N.L. Anderson, N.G. Anderson, The human plasma proteome: history, character, and diagnostic prospects, *Mol. Cell. Proteom.* 1 (11) (2002) 845–867, PMID: 12488461.
- [30] H. Borsook, C.E. Jeffreys, Glutathione and ascorbic acid, *Science* 83 (2156) (1936) 397–398, PMID: 17831284.
- [31] J. Lykkesfeldt, Determination of ascorbic acid and dehydroascorbic acid in biological samples by high-performance liquid chromatography using subtraction methods: reliable reduction with tris[2-carboxyethyl]phosphine hydrochloride, *Anal. Biochem.* 282 (1) (2000) 89–93, PMID: 10860503.
- [32] B.S. Winkler, S.M. Orselli, T.S. Rex, The redox couple between glutathione and ascorbic acid: a chemical and physiological perspective, *Free Radic. Biol. Med.* 17 (4) (1994) 333–349, PMID: 8001837.